TrialThe oncologist2026

Pembrolizumab combined with disitamab vedotin in human epidermal growth factor receptor 2-positive metastatic colorectal cancer.

Xiaojing Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.